

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE DISTRICT OF DELAWARE**

In re:

INSYS THERAPEUTICS, INC., *et al.*,

Liquidating Debtors.<sup>1</sup>

Chapter 11

Case No. 19-11292 (JTD)

(Jointly Administered)

**Re: D.I. 1708**

**ORDER GRANTING FOURTEENTH OMNIBUS OBJECTION OF THE TRUSTEE OF  
THE INSYS LIQUIDATION TRUST TO CLAIMS (NON-SUBSTANTIVE)  
(Amended and Superseded, Insufficient Documentation, and Late Filed Claims)**

Upon the *Fourteenth Omnibus Objection of the Trustee of the Insys Liquidation Trust to Claims* (the “Objection”) for entry of an order disallowing and expunging the claims set forth on Exhibits 1, 2, and 3 (each a “Claim” and collectively, the “Claims”), all as more fully set forth in the Objection; and upon the *Declaration of Edward A. Phillips Pursuant to 28 U.S.C. § 1746 and Local Rule 3007-1 in Support of the Fourteenth Omnibus Objection of the Trustee of the Insys Liquidation Trust to Claims* filed contemporaneously with the Objection and in support thereof; and this Court having jurisdiction to consider the Objection and the relief requested therein pursuant to 28 U.S.C. §§ 157 and 1334; and consideration of the Objection and the relief requested therein being a core proceeding pursuant to 28 U.S.C. § 157(b); and venue being proper before this Court pursuant to 28 U.S.C. §§ 1408 and 1409; and due and proper notice of the Objection having been provided, and no other or further notice being required; and the Court having considered all responses to the Objection, if any, and all such responses having been either overruled or withdrawn; and upon all proceedings had before the Court; and the Court

---

<sup>1</sup> The Liquidating Debtors in these cases, along with the last four digits of each Debtor’s federal tax identification number, are: Insys Therapeutics, Inc. (7886); IC Operations, LLC (9659), Insys Development Company, Inc. (3020); Insys Manufacturing, LLC (0789); Insys Pharma, Inc. (9410); IPSC, LLC (6577); and IPT 355, LLC (0155).

having determined that the legal and factual bases set forth in the Objection establish just cause for the relief granted herein; and

This Court having **FOUND AND DETERMINED THAT:**

A. The holders of the Claims listed on **Exhibits 1, 2 and 3** attached hereto were properly and timely served with a copy of the Objection and all of its accompanying exhibits and notice of a hearing on the Objection and response deadline,

B. Any entity known to have an interest in the Claims subject to the Objection has been afforded reasonable opportunity to respond to, or be heard regarding, the relief requested in the Objection, and

C. The relief requested in the Objection is in the best interests of the Liquidation Trust, its beneficiaries, the Debtors, their estates, their creditors, and other parties in interest; And after due deliberation and sufficient cause appearing therefor,

**IT IS THEREFORE ORDERED THAT:**

1. The Objection is **GRANTED**.
2. The Claims listed in the column entitled “Amended Claims to be Disallowed” on **Exhibit 1** attached hereto are hereby disallowed and expunged in their entirety.
3. The Claims listed on **Exhibits 2 and 3** hereto are hereby disallowed and expunged in their entirety.
4. Epiq Corporate Restructuring, LLC is authorized and directed to disallow and expunge the Claims listed on **Exhibits 1, 2 and 3** as reflected therein on the official claims registry pursuant to this Order and to make other changes to the official claims registry as necessary to reflect the terms of this Order.
5. Each Claim addressed in the Objection constitutes a separate contested matter as

contemplated by Bankruptcy Rule 9014. This Order shall be deemed a separate Order with respect to each Claim. Any stay of this Order pending appeal by any of the claimants whose Claims are subject to this Order shall apply only to the contested matter which involves such claimant and shall not act to stay the applicability and/or finality of this Order with respect to other contested matters covered hereby.


6. Nothing contained in the Objection or this Order is intended to be or shall be deemed as (i) an admission as to the validity of any claim against the Debtors or its estates, (ii) waiver of rights to dispute the amount of, basis for, or validity of any claim, (iii) a waiver of rights under Bankruptcy Code or any applicable non-bankruptcy law, (iv) an agreement or obligation to pay any claims, or (v) a waiver of any claims or causes of action which may exists against any creditor or interest holder.

7. Nothing in the Objection or this Order shall be construed as an allowance of any Claim.

8. The Trustee's rights to amend, modify, or supplement the Objection, to file additional objections to the Claims, any other claims (filed or not) which have or may be asserted against the Debtors or their estates, and to seek further reduction of any Claim, are preserved. Additionally, should the grounds of objection stated in the Objection be dismissed, the Trustee's right to object on other stated grounds or any other grounds that the Trustee discovers during the pendency of these cases are further preserved.

9. This Court shall retain jurisdiction to hear and determine all matters arising from the interpretation and/or implementation of this Order.

**Dated: July 16th, 2021**  
**Wilmington, Delaware**

  
**JOHN T. DORSEY**  
**UNITED STATES BANKRUPTCY JUDGE**

**Fourteenth Omnibus Claims Objection  
Exhibit 1 - Amended and Superseded Claims**

Amended Claims to be Disallowed					Surviving Claims			
Name	Claim or Scheduled #	Debtor	Disallowed Asserted Amount	Reason for Disallowance	Name	Claim or Schedule	Debtor	Surviving Asserted Amount
ADLER POLLOCK & SHEEHAN PC	292000470 296000030	Insys Therapeutics, Inc. Insys Pharma, Inc.	\$28,750.62 \$28,739.25	Claims are amended and superseded by the surviving claim.	ADLER POLLOCK & SHEEHAN PC	328	Insys Therapeutics, Inc.	\$77,444.47
GOODELL, DEVRIES, LEECH & DANN, LLP	292024580 2960000620	Insys Therapeutics, Inc. Insys Pharma, Inc.	\$57,153.89 \$4,951.98	Claims are amended and superseded by the surviving claim.	GOODELL, DEVRIES, LEECH & DANN, LLP	10429	Insys Therapeutics, Inc.	\$60,129.41

**Fourteenth Omnibus Claims Objection  
Exhibit 2 - Insufficient Documentation Claims**

<u>Name</u>	<u>Claim No.</u>	<u>Debtor</u>	<u>Claim Amount</u>	<u>Classification</u>	<u>Reason for Disallowance</u>
DEPARTMENT OF TAXATION - STATE OF HAWAII*	2627	Insys Pharma, Inc.	\$ 998,28	Priority- 11 U.S.C. Section 507(a)(8)	Claim does not provide sufficient or any documentation to determine the validity or amount of the claim.
HAMILTON, MALENDIA *	10615	Insys Therapeutics, Inc.	Undetermined	Priority- 11 U.S.C. Section 507(a)(4)	Claim does not provide sufficient or any documentation to determine the validity or amount of the claim.
LIFESTREAM BEHAVIORAL CENTER INC.*	2624	Insys Therapeutics, Inc.	Undetermined	General unsecured	Claim does not provide sufficient or any documentation to determine the validity or amount of the claim.
RAMEY, E. SHANF*	1585	Insys Therapeutics, Inc.	\$ 54.78	Secured	Claim does not provide sufficient or any documentation to determine the validity or amount of the claim.
YOHO, MICHELLE D.*	890	Insys Therapeutics, Inc.	\$ 711.00	Priority- 11 U.S.C. Section 507(a)(4)	Claim does not provide sufficient or any documentation to determine the validity or amount of the claim.

\*These claims are also being objected to as Late Filed Claims. See Exhibit 3.

**Fourteenth Omnibus Claims Objection  
Exhibit 3 – Late Filed Claims**

<u>Name</u>	<u>Claim No.</u>	<u>Filed Date</u>	<u>Debtor</u>	<u>Claim Amount</u>	<u>Classification</u>	<u>Reason for Disallowance</u>
DEPARTMENT OF TAXATION- STATE OF HAWAII*	2627	3/30/2021	Insys Pharma, Inc.	\$ 998.28	Priority- 11 U.S.C. Section 507(a)(8)	Filed after applicable bar date.
HAMILTON, MALENDIA*	10615	9/24/2019	Insys Therapeutics, Inc.	Undetermined	Priority- 11 U.S.C. Section 507(a)(4)	Filed after applicable bar date.
LIFESTREAM BEHAVIORAL CENTER INC.*	2624	2/18/2021	Insys Therapeutics, Inc.	Undetermined	General unsecured	Filed after applicable bar date.
NEW YORK STATE DEPARTMENT OF LABOR	2623	12/16/2020	IPSC, LLC	\$ 118.53	Priority- 11 U.S.C. Section 507(a)(8)	Filed after applicable bar date.
RAMEY, E. SHANE*	1585	10/16/2019	Insys Therapeutics, Inc.	\$ 54.78	Secured	Filed after applicable bar date.
YOHO, MICHELLE D.*	890	10/7/2019	Insys Therapeutics, Inc.	\$ 711.00	Priority- 11 U.S.C. Section 507(a)(4)	Filed after applicable bar date.

\*These claims are also being objected to as Insufficient Documentation Claims. See Exhibit 2.